Morphine News and Research

Latest Morphine News and Research

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

New research: Retired NFL players more likely to misuse painkillers

Retired NFL players use painkillers at a much higher rate than the rest of us, according to new research conducted by investigators at Washington University School of Medicine in St. Louis.

28 Jan 2011

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in the peer-reviewed journal Pain Practice concluded that IV ibuprofen significantly reduced both morphine use and self-reported pain intensity in patients recovering from abdominal hysterectomy compared to morphine alone.

27 Jan 2011

PecFent accepted in Scotland for treatment of breakthrough cancer pain

Archimedes Pharma Ltd., a leading international specialty pharma company, today announced the decision by the Scottish Medicines Consortium to accept PecFent for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

18 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Study suggests new experimental drug is better than standard morphine

A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist has found.

5 Jan 2011

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.

14 Dec 2010

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BioDelivery Sciences International, Inc. today announced the enrollment and dosing of the first patient in its Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

9 Dec 2010

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.

5 Dec 2010

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

Exposure to nicotine during pregnancy leads to a decrease in adult stem cells and a change in synaptic plasticity in the hippocampus of the offspring, according to new research from the University of Alabama at Birmingham presented at Neuroscience 2010, the annual Society for Neuroscience meeting in San Diego in November.

4 Dec 2010

New study finds no decrease in patient harm at hospitals

Despite concerted efforts, no decreases in patient harm were detected at 10 randomly selected North Carolina hospitals between 2002 and 2007, according to a new study from the Stanford University School of Medicine, Harvard Medical School and the Institute for Healthcare Improvement.

25 Nov 2010

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

24 Nov 2010

Ziconotide could promote suicidal tendencies: Study

The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly suspected of causing patients to commit suicide. Researchers working under the auspices of Prof. Christoph Maier (Director of the Pain Clinic Bergmannsheil at the Ruhr University in Bochum) presume that ziconotide not only suppresses the transmission of pain stimuli, but also deteriorates the frame of mind and could simultaneously reduce anxiety and impulse control.

23 Nov 2010

New findings help identify impact of prenatal environment on early parental care on brain

New findings released today help identify the long-term impact of the prenatal environment and early parental care on the brain. Using animals as models, researchers help explain why early inflammation and a mother's exposure to drugs such as nicotine and high doses of pain killers have lasting consequences for children and even future generations.

16 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Morphine News and Research

Latest Morphine News and Research

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

New research: Retired NFL players more likely to misuse painkillers

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

PecFent accepted in Scotland for treatment of breakthrough cancer pain

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Study suggests new experimental drug is better than standard morphine

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

New study finds no decrease in patient harm at hospitals

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

Ziconotide could promote suicidal tendencies: Study

New findings help identify impact of prenatal environment on early parental care on brain

New noninvasive technique provides low-level electrical stimulation to reduce pain

Single injection of morphine to fight persistent pain reduces testosterone level: Research

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Nitric oxide inhalation reduces pain in sickle cell disease patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Morphine News and Research

Latest Morphine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in